Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298775778> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W4298775778 endingPage "30" @default.
- W4298775778 startingPage "225" @default.
- W4298775778 abstract "The relative efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) for the treatment of Guillain-Barré syndrome has not been established. We compared PE with IVIg, and with a combined regimen of PE followed by IVIg, in an international, multicentre, randomised trial of 383 adult patients with Guillain-Barré syndrome.The patients were randomly assigned PE (five 50 mL/kg exchanges over 8-13 days), IVIg (Sandoglobulin, 0.4 g/kg daily for 5 days), or the PE course immediately followed by the IVIg course. The inclusion criteria were severe disease (aid needed for walking) and onset of neuropathic symptoms within the previous 14 days. Patients were followed up for 48 weeks.Four patients were excluded because they did not meet the randomisation criteria. All the remaining 379 patients were assessed for the major outcome criterion-change on a seven-point disability grade scale-by an observer unaware of treatment assignment, 4 weeks after randomisation. At that time, the mean improvement was 0.9 (SD 1.3) in the 121 PE-group patients, 0.8 (1.3) in the 130 IVIg-group patients, and 1.1 (1.4) in the 128 patients who received both treatments (intention-to-treat analysis). None of the differences between the groups for this major outcome criterion was significant. The difference between PE alone and IVIg alone was so small that a 0.5 grade difference was excluded at the 95% level of confidence. There was no significant difference between any of the treatment groups in the secondary outcome measures: time to recovery of unaided walking, time to discontinuation of ventilation, and trend describing the recovery from disability up to 48 weeks. There was a non-significant trend towards a more favourable outcome on some outcome measures with combined treatment.In treatment of severe Guillain-Barré syndrome during the first 2 weeks after onset of neuropathic symptoms, PE and IVIg had equivalent efficacy. The combination of PE with IVIg did not confer a significant advantage." @default.
- W4298775778 created "2022-10-02" @default.
- W4298775778 date "1997-01-25" @default.
- W4298775778 modified "2023-10-17" @default.
- W4298775778 title "Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group." @default.
- W4298775778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9014908" @default.
- W4298775778 hasPublicationYear "1997" @default.
- W4298775778 type Work @default.
- W4298775778 citedByCount "96" @default.
- W4298775778 countsByYear W42987757782013 @default.
- W4298775778 countsByYear W42987757782014 @default.
- W4298775778 countsByYear W42987757782015 @default.
- W4298775778 countsByYear W42987757782016 @default.
- W4298775778 countsByYear W42987757782017 @default.
- W4298775778 countsByYear W42987757782018 @default.
- W4298775778 countsByYear W42987757782019 @default.
- W4298775778 countsByYear W42987757782020 @default.
- W4298775778 countsByYear W42987757782021 @default.
- W4298775778 countsByYear W42987757782022 @default.
- W4298775778 countsByYear W42987757782023 @default.
- W4298775778 crossrefType "journal-article" @default.
- W4298775778 hasConcept C126322002 @default.
- W4298775778 hasConcept C141071460 @default.
- W4298775778 hasConcept C168563851 @default.
- W4298775778 hasConcept C187212893 @default.
- W4298775778 hasConcept C2778691916 @default.
- W4298775778 hasConcept C2781413609 @default.
- W4298775778 hasConcept C44249647 @default.
- W4298775778 hasConcept C71924100 @default.
- W4298775778 hasConceptScore W4298775778C126322002 @default.
- W4298775778 hasConceptScore W4298775778C141071460 @default.
- W4298775778 hasConceptScore W4298775778C168563851 @default.
- W4298775778 hasConceptScore W4298775778C187212893 @default.
- W4298775778 hasConceptScore W4298775778C2778691916 @default.
- W4298775778 hasConceptScore W4298775778C2781413609 @default.
- W4298775778 hasConceptScore W4298775778C44249647 @default.
- W4298775778 hasConceptScore W4298775778C71924100 @default.
- W4298775778 hasIssue "9047" @default.
- W4298775778 hasLocation W42987757781 @default.
- W4298775778 hasOpenAccess W4298775778 @default.
- W4298775778 hasPrimaryLocation W42987757781 @default.
- W4298775778 hasRelatedWork W1989160339 @default.
- W4298775778 hasRelatedWork W2002120878 @default.
- W4298775778 hasRelatedWork W2003938723 @default.
- W4298775778 hasRelatedWork W2047967234 @default.
- W4298775778 hasRelatedWork W2118496982 @default.
- W4298775778 hasRelatedWork W2313532716 @default.
- W4298775778 hasRelatedWork W2439875401 @default.
- W4298775778 hasRelatedWork W4238867864 @default.
- W4298775778 hasRelatedWork W2519357708 @default.
- W4298775778 hasRelatedWork W2525756941 @default.
- W4298775778 hasVolume "349" @default.
- W4298775778 isParatext "false" @default.
- W4298775778 isRetracted "false" @default.
- W4298775778 workType "article" @default.